In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Adamis Pharma (ADMP – Research Report), with a price target of $10. The company’s shares closed yesterday at $2.79.
“Adamis provided an update on the coming US launch of Symjepi 0.3mg. The product is expected to launch in 1Q19 through commercial partner Sandoz (Novartis, NVS – NR). We note that Adamis maintains the ex-US rights to Symjepi and we could see additional commercial partnerships, which represent potential future catalysts.”
According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.9% and a 30.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Currently, the analyst consensus on Adamis Pharma is a Strong Buy with an average price target of $7.
The company has a one-year high of $5.10 and a one-year low of $2.20. Currently, Adamis Pharma has an average volume of 664.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adamis Pharmaceuticals Corp. is a biopharmaceutical company which is focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy.. Its activities include the combination of pharmaceuticals and biotechnology to produce medicines for patients, and physicians.